Colostrum and the Economics of Suppression

The takehome is that we can use colostrum to defeat flue problems.  Yet our drug industry regime lovks it out.

We need a completely new and novel approval protocol to fix this.

And it will never come from big pharma.

The Buried Alternative: Colostrum and the Economics of Suppression

In 2007, Cesarone and colleagues published in Clinical and Applied Thrombosis/Hemostasis that bovine colostrum was approximately three times more effective than vaccination at preventing flu episodes. Among high-risk cardiovascular patients, the colostrum group experienced zero hospitalizations, while the vaccinated group suffered multiple hospitalizations and one death. Total flu-related costs in the colostrum group were 30% of the vaccinated group—a 70% cost reduction. No significant side effects.6

Belcaro et al. (2010) confirmed and extended these findings.7 The mechanism is fundamentally different from vaccination: broad-spectrum immune enhancement through secretory IgA, lactoferrin, cytokine modulation, and gut-immune axis support. It is pathogen-agnostic—it doesn’t require predicting which strains will circulate.

Bovine colostrum cannot be patented. Without patent protection, no pharmaceutical company will invest the $50–100 million required for Phase III trials. The influenza vaccine market was valued at $7.97 billion in 2023 and is projected to reach $17.77 billion by 2032.12 The same structural logic explains why vitamin D—shown to reduce influenza A risk by 59% in children at 1,200 IUs daily13—and elderberry, echinacea, ginseng, green tea, and probiotics remain absent from policy conversations despite published peer-reviewed evidence.3